Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14553917 | 0.87 | OGT (0.77) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL15788589 | 0.87 | OGT (0.77) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL14553921 | 0.83 | ALDH1A1 (0.71) | OGTALDH1A1ASAH1IDO1KMT2A | |
| SCHEMBL8698097 | 0.80 | IDO1 (0.68) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL23815651 | 0.76 | IDO1 (0.77) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL15788594 | 0.76 | OGT (0.62) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL14553919 | 0.75 | OGT (0.60) | OGTALDH1A1ASAH1IDO1KMT2A | |
| SCHEMBL15788588 | 0.74 | OGT (0.59) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL14553929 | 0.74 | OGT (0.59) | OGTALDH1A1TP53ASAH1IDO1 | |
| SCHEMBL15788586 | 0.73 | ALDH1A1 (0.64) | OGTALDH1A1TP53IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009086952-A2 | COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE ARTICULAR DISEASES | PROJECH SCIENCE TO TECHNOLOGY, S.L. (ES) | 2009-07-16 | — | — | WO | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-9645151-B2 | Targeting phosphofructokinase and its glycosylation form for cancer | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9645151-B2 | Targeting phosphofructokinase and its glycosylation form for cancer | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9573911-B2 | Diphosphate mimetics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573911-B2 | Diphosphate mimetics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150369809-A1 | TARGETING PHOSPHOFRUCTOKINASE AND ITS GLYCOSYLATION FORM FOR CANCER | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-24 | — | — | US | disclosed |
| US-20150369809-A1 | TARGETING PHOSPHOFRUCTOKINASE AND ITS GLYCOSYLATION FORM FOR CANCER | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-24 | — | — | US | disclosed |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013006758-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-31 | — | — | US | disclosed |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | OGT 3728/4885ALDH1A1 4306/4885TP53 3071/4885 |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PLK1, OGA, MAPKAPK2 | OGT 4/4885ALDH1A1 3317/4885TP53 1456/4885 |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | IAPP, OGA, IDE | OGT 31/4885ALDH1A1 4021/4885TP53 2379/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | OGT 815/4885ALDH1A1 4642/4885TP53 1248/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | OGT 815/4885ALDH1A1 4642/4885TP53 1248/4885 |
| US-20150369809-A1 | TARGETING PHOSPHOFRUCTOKINASE AND ITS GLYCOSYLATION FORM FOR CANCER | PFKFB1, PFKFB2, PGK1 | OGT 44/4885ALDH1A1 895/4885TP53 95/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | OGT 3673/4885ALDH1A1 4788/4885TP53 3471/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | OGT 3760/4885ALDH1A1 4814/4885TP53 3984/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | OGT 1605/4885ALDH1A1 4687/4885TP53 2239/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | OGT 610/4885ALDH1A1 4592/4885TP53 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.